Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Recondo, G; Mezquita, L; Facchinetti, F; Planchard, D; Gazzah, A; Bigot, L; Rizvi, AZ; Frias, RL; Thiery, JP; Scoazec, JY; Sourisseau, T; Howarth, K; Deas, O; Samofalova, D; Galissant, J; Tesson, P; Braye, F; Naltet, C; Lavaud, P; Mahjoubi, L; Abou Lovergne, A; Vassal, G; Bahleda, R; Hollebecque, A; Nicotra, C; Ngo-Camus, M; Michiels, S; Lacroix, L; Richon, C; Auger, N; De Baere, T; Tselikas, L; Solary, E; Angevin, E; Eggermont, AM; Andre, F; Massard, C; Olaussen, KA; Soria, JC; Besse, B; Friboulet, L

Friboulet, L (corresponding author), Univ Paris Saclay, Gustave Roussy Canc Campus, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.

CLINICAL CANCER RESEARCH, 2020; 26 (1): 242

Abstract

Purpose: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearran......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索